Cargando…
Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity
Cardiotoxicity is a well-known complication following treatment with anthracyclines. However, they are still widely used in chemotherapy for breast cancer, lymphoma, leukemia, and sarcoma, among others. Patient clinical characteristics, such as age, sex, comorbidities, anthracycline dose and infusio...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Internal Medicine
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939510/ https://www.ncbi.nlm.nih.gov/pubmed/27378126 http://dx.doi.org/10.3904/kjim.2016.017 |
_version_ | 1782442013859250176 |
---|---|
author | Chung, Woo-Baek Youn, Ho-Joong |
author_facet | Chung, Woo-Baek Youn, Ho-Joong |
author_sort | Chung, Woo-Baek |
collection | PubMed |
description | Cardiotoxicity is a well-known complication following treatment with anthracyclines. However, they are still widely used in chemotherapy for breast cancer, lymphoma, leukemia, and sarcoma, among others. Patient clinical characteristics, such as age, sex, comorbidities, anthracycline dose and infusion schedule, and the combined anti-cancer agents used, are diverse among cancer types. It is difficult to recommend guidelines for the prevention or management of anthracycline-induced cardiotoxicity applicable to all cancer types. Therefore, anthracycline-induced cardiotoxicity remains a major limitation in the proper management of cancer patients treated with an anthracycline-combined regimen. Efforts have been extensive to determine the mechanism and treatment of anthracycline-induced cardiotoxicity. Because cardiotoxicity causes irreversible damage to the myocardium, prevention is a more effective approach than treatment of cardiotoxicity after symptomatic or asymptomatic cardiac dysfunction develops. This article will review the pathophysiological mechanisms of anthracycline-induced cardiotoxicity and strategies for protecting the myocardium from anthracycline. |
format | Online Article Text |
id | pubmed-4939510 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | The Korean Association of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-49395102016-07-11 Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity Chung, Woo-Baek Youn, Ho-Joong Korean J Intern Med Review Cardiotoxicity is a well-known complication following treatment with anthracyclines. However, they are still widely used in chemotherapy for breast cancer, lymphoma, leukemia, and sarcoma, among others. Patient clinical characteristics, such as age, sex, comorbidities, anthracycline dose and infusion schedule, and the combined anti-cancer agents used, are diverse among cancer types. It is difficult to recommend guidelines for the prevention or management of anthracycline-induced cardiotoxicity applicable to all cancer types. Therefore, anthracycline-induced cardiotoxicity remains a major limitation in the proper management of cancer patients treated with an anthracycline-combined regimen. Efforts have been extensive to determine the mechanism and treatment of anthracycline-induced cardiotoxicity. Because cardiotoxicity causes irreversible damage to the myocardium, prevention is a more effective approach than treatment of cardiotoxicity after symptomatic or asymptomatic cardiac dysfunction develops. This article will review the pathophysiological mechanisms of anthracycline-induced cardiotoxicity and strategies for protecting the myocardium from anthracycline. The Korean Association of Internal Medicine 2016-07 2016-07-01 /pmc/articles/PMC4939510/ /pubmed/27378126 http://dx.doi.org/10.3904/kjim.2016.017 Text en Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Chung, Woo-Baek Youn, Ho-Joong Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity |
title | Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity |
title_full | Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity |
title_fullStr | Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity |
title_full_unstemmed | Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity |
title_short | Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity |
title_sort | pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939510/ https://www.ncbi.nlm.nih.gov/pubmed/27378126 http://dx.doi.org/10.3904/kjim.2016.017 |
work_keys_str_mv | AT chungwoobaek pathophysiologyandpreventivestrategiesofanthracyclineinducedcardiotoxicity AT younhojoong pathophysiologyandpreventivestrategiesofanthracyclineinducedcardiotoxicity |